Female nonsmokers exposed to passive smoking >30 years have increased risk of lung cancer
the ONA take:
According to a new study published in the journal Annals of Oncology, researchers from Stanford University School of Medicine in Stanford, California, have found that women who are exposed to smoking in the home for greater than 30 years have an increased risk for developing lung cancer despite having never smoked compared with women who were not exposed to passive smoking.
For the study, researchers identified 76,304 women between the ages 50 and 79 years. Of those, 6.2% were current smokers, 41.68% were former smokers, 47.36% were nonsmokers but exposed to passive smoking, and 4.77% were never smokers and had no exposure to passive smoking. The women were followed for an average of 10.5 years.
During that time, 901 women developed lung cancer. Results showed that current smokers were 13.44 times more likely to develop lung cancer compared with never-smokers, and former smokers were 4.2 times more likely than never-smokers.
There was no statistically significant difference of risk between non-smokers with passive smoking exposure and those without passive smoking exposure. When researchers conducted subgroup analyses, there was a borderline significant risk of lung cancer among nonsmokers exposed to passive smoking for more than 30 years versus women with no home exposure (HR = 1.61).
Women who are exposed to smoking in the home for greater than 30 years have an increased risk.
The analysis also found that women who smoke are 13 times more likely to develop lung cancer than those who have never smoked, but quitting significantly reduces this risk. The study, published in Annals of Oncology, used data from the Women's Health Initiative Observational Study cohort to investigate the relationship between active and passive smoking and lung cancer incidence in women.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|